MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INKT MiNK Therapeutics, Inc.

Pre-Mkt 06-11 09:25:00 EDT

12.19

+0.37

+3.13%

盘前11.50

-0.69-5.66%

08:46 EDT

High12.49	Low11.78	Vol27.88K
Open11.90	D1 Closing11.82	Amplitude6.01%
Mkt Cap60.53M	Tradable Cap20.44M	Total Shares4.97M
T/O334.70K	T/O Rate1.66%	Tradable Shares1.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INKT","market":"US","secType":"STK","nameCN":"MiNK Therapeutics, Inc.","latestPrice":12.19,"timestamp":1781121600000,"preClose":11.82,"halted":0,"volume":27877,"hourTrading":{"tag":"盘前","latestPrice":11.5,"preClose":12.19,"latestTime":"08:46 EDT","volume":111,"amount":1351.675527,"timestamp":1781181988703,"change":-0.69,"changeRate":-0.056604,"amplitude":0.06525},"delay":0,"changeRate":0.03130287648054139,"floatShares":1677000,"shares":4965858,"eps":-2.784285,"marketStatus":"Pre-Mkt","change":0.37,"latestTime":"06-11 09:25:00 EDT","open":11.9,"high":12.485,"low":11.775,"amount":334703.72301899997,"amplitude":0.060068,"askPrice":12.25,"askSize":77,"bidPrice":11.5,"bidSize":21,"shortable":3,"etf":0,"ttmEps":-2.784285,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1781184600000},"marketStatusCode":1,"adr":0,"listingDate":1634270400000,"exchange":"NASDAQ","adjPreClose":12.19,"preHourTrading":{"tag":"盘前","latestPrice":11.5,"preClose":12.19,"latestTime":"08:46 EDT","volume":111,"amount":1351.675527,"timestamp":1781181988703,"change":-0.69,"changeRate":-0.056604,"amplitude":0.06525},"postHourTrading":{"tag":"盘后","latestPrice":12.19,"preClose":12.19,"latestTime":"19:46 EDT","volume":236,"amount":2746.245,"timestamp":1781135178722,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7923583937325138},"requestUrl":"/m/hq/s/INKT/wiki","defaultTab":"wiki","newsList":[{"id":"2641125057","title":"MiNK Therapeutics Rocked by Fresh Insider Share Sale","url":"https://stock-news.laohu8.com/highlight/detail?id=2641125057","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641125057?lang=en_us&edition=fundamental","pubTime":"2026-06-06 10:08","pubTimestamp":1780711716,"startTime":"0","endTime":"0","summary":"New insider activity at MiNK Therapeutics ( ($INKT) ) has taken place on June 5, 2026. Director Barbara Ryan has recently sold 1,500 shares of MiNK...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/mink-therapeutics-rocked-by-fresh-insider-share-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/mink-therapeutics-rocked-by-fresh-insider-share-sale-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641128246","title":"MiNK Therapeutics director Barbara Ryan disposes of 1,500 common shares worth $19,143.25","url":"https://stock-news.laohu8.com/highlight/detail?id=2641128246","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641128246?lang=en_us&edition=fundamental","pubTime":"2026-06-06 06:04","pubTimestamp":1780697076,"startTime":"0","endTime":"0","summary":"Mink Therapeutics director Barbara Ryan sold 1,500 shares of common stock on June 4, 2026.Sales priced at USD 12.68 to USD 12.8 per share.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 05, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nNDL2NmN4N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"MiNK Therapeutics director Barbara Ryan disposes of 1,500 common shares worth $19,143.25","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640181711","title":"MiNK Therapeutics announces virtual annual shareholders meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640181711","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640181711?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:32","pubTimestamp":1780518738,"startTime":"0","endTime":"0","summary":"Mink Therapeutics will hold its 2026 annual shareholders meeting in a virtual-only format on June 17, 2026.The company will provide a live webcast of the meeting, with a replay available afterward.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260603:nNDLhYp6r:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014021.USD","LU2210150020.SGD","BK4112","LU0314104364.USD","BK4588","INKT","SG9999014039.USD","SG9999014013.SGD","BK4139","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","NDAQ","IE00BKPKM429.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640588184","title":"MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640588184","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640588184?lang=en_us&edition=fundamental","pubTime":"2026-06-04 04:30","pubTimestamp":1780518600,"startTime":"0","endTime":"0","summary":"NEW YORK, June  03, 2026  (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc.(NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) c","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3306402/0/en/MiNK-Therapeutics-Announces-its-Virtual-2026-Annual-Shareholders-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639690209","title":"BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl's","url":"https://stock-news.laohu8.com/highlight/detail?id=2639690209","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639690209?lang=en_us&edition=fundamental","pubTime":"2026-05-29 01:41","pubTimestamp":1779990094,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Snowflake, Best Buy, Kohl'sWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: ht","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nL6N4250NZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PLAB","INKT","SUGP","AU","SNPS","UMAC","CRM","CDE","TSN","MASK","DAVE","SIDU","NEM","NSC","AMPX","A","COGT","LLY","MRVL","NBIS","SNOW","ZCMD","P","NEMG","PWR","NEBX","CVX","UNP","MOD","SPRC","KSS","CGTL","NEOV","D","AVEX","HLXX","APA","HPQ","HL","HRL","CZR","MMM","BTU","BBY","BURL","SNOU","DLTR","XOM","NEE","FANG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638691600","title":"MiNK Therapeutics doses first patient in agenT-797 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638691600","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638691600?lang=en_us&edition=fundamental","pubTime":"2026-05-28 22:12","pubTimestamp":1779977523,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) announced that the first patient has been dosed in its randomized Phase 2 clinical trial evaluating agenT-797 with standar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-doses-first-patient-in-agent-797-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-doses-first-patient-in-agent-797-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638975699","title":"BUZZ-MiNK Therapeutics jumps after first patient dosed in lung injury study","url":"https://stock-news.laohu8.com/highlight/detail?id=2638975699","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638975699?lang=en_us&edition=fundamental","pubTime":"2026-05-28 21:49","pubTimestamp":1779976154,"startTime":"0","endTime":"0","summary":"BUZZ-MiNK Therapeutics jumps after first patient dosed in lung injury study** Shares of drug developer MiNK Therapeutics INKT.O rise 10.8% to $11.28 ** The firm says it has dosed the first patient in a mid-stage study of agenT-797, its experimental cell therapy for severe acute lung injury and critical illness — a condition where patients struggle to breathe and may need ventilator support ** Study will test whether adding agenT-797 to standard care can help patients survive, recover faster in ICU and spend fewer days on ventilators - INKT ** Adds that severe acute lung injury carries an 40%+ death rate, with no approved treatment shown to lower mortality** Trial began in Ukraine, with U.S. site expansion underway; preliminary data expected in H2 2026 - INKT** Including session's move, INKT up 0.13% YTD   ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nL4N4251DZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638696555","title":"Mink Therapeutics doses first patient in Phase 2 agenT-797 acute lung injury trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2638696555","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638696555?lang=en_us&edition=fundamental","pubTime":"2026-05-28 21:10","pubTimestamp":1779973855,"startTime":"0","endTime":"0","summary":"Mink Therapeutics dosed the first patient in a randomized Phase 2 trial of agenT-797 for severe acute lung injury meeting global ARDS criteria.Study compares agenT-797 with standard of care versus placebo with standard of care in critically ill ICU patients.Results have not been presented; preliminary data are expected in the second half of 2026.Trial aims to show whether the therapy can improve ICU recovery and survival outcomes in a setting with no mortality-reducing treatments.Program expands the company’s iNKT cell platform into critical care, with U.S. IND-backed plans to add sites.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief on May 28, 2026,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDL2zVcMF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638695006","title":"Mink Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of Agent-797 in Acute Lung Injury and Critical Illness","url":"https://stock-news.laohu8.com/highlight/detail?id=2638695006","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638695006?lang=en_us&edition=fundamental","pubTime":"2026-05-28 21:04","pubTimestamp":1779973489,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA2XCDP0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636826153","title":"MiNK Therapeutics reports new data on agenT-797 at ATS 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2636826153","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636826153?lang=en_us&edition=fundamental","pubTime":"2026-05-20 23:15","pubTimestamp":1779290148,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (INKT) announced new clinical and translational data presented at the American Thoracic Society International Conference 2026 and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-reports-new-data-on-agent-797-at-ats-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mink-therapeutics-reports-new-data-on-agent-797-at-ats-2026-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT","BK4161","BK4139","ATS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636826375","title":"Mink Therapeutics starts Phase 2 trial of agenT-797 in severe acute lung injury","url":"https://stock-news.laohu8.com/highlight/detail?id=2636826375","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636826375?lang=en_us&edition=fundamental","pubTime":"2026-05-20 23:07","pubTimestamp":1779289655,"startTime":"0","endTime":"0","summary":"Mink Therapeutics reported new clinical and translational data on its investigational allo-iNKT cell therapy agenT-797 at the American Thoracic Society International Conference 2026, with the case study also published in Clinical Immunology Communications.The sequential regimen pairing agenT-797 with ImmunityBio’s IL-15 superagonist N-803 was linked to pathogen suppression, signs of lung immune recovery, reduced inflammatory signaling, and activation of tissue repair pathways in a critically ill patient with disseminated Coccidioides infection, ARDS, and hospital-acquired Pseudomonas pneumonia.The patient later transitioned to comfort care due to recurrent cardiac decompensation, with investigators attributing the likely terminal mechanism to acute heart failure rather than cytokine release or infection.The update supports an ongoing randomized Phase 2 trial testing agenT-797 with standard of care versus placebo with standard of care in ICU patients with severe acute lung injury and ac","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260520:nNDLc2537c:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","IBRX","IE00BN0W2T93.GBP","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0314104364.USD","BK4112","LU2210149790.SGD","LU2095319765.USD","LU2210150020.SGD","NDAQ","SG9999014021.USD","BK4139","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4588","IE00BN0W2W23.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636265708","title":"MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=2636265708","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636265708?lang=en_us&edition=fundamental","pubTime":"2026-05-20 23:07","pubTimestamp":1779289620,"startTime":"0","endTime":"0","summary":"agenT-797 demonstrates pathogen suppression, lung immune restoration and tissue repair activation, supporting Ongoing Phase 2 trialSequential immunotherapy with agenT-797 and N-803, an FDA-approved IL","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/20/3298712/0/en/MiNK-Therapeutics-Reports-New-Data-on-agenT-797-an-allo-iNKT-Cell-Therapy-at-ATS-2026-Simultaneously-Published-in-Clinical-Immunology-Communications.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4161","INKT","BK4139","ARDS","ATS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636107227","title":"MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2636107227","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636107227?lang=en_us&edition=fundamental","pubTime":"2026-05-18 23:22","pubTimestamp":1779117720,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INKT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 18, 2026 11:22 ET (15:22 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636012042","title":"Analysts Are Bullish on These Healthcare Stocks: Biofrontera (BFRI), MiNK Therapeutics (INKT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636012042","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636012042?lang=en_us&edition=fundamental","pubTime":"2026-05-18 14:30","pubTimestamp":1779085811,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Biofrontera (BFRI) and MiNK Therapeutics (INKT) with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-biofrontera-bfri-mink-therapeutics-inkt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-biofrontera-bfri-mink-therapeutics-inkt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT","BK4112","BK4588","BLSG","BK4007","BFRI","BLSX","BK4137","LU0128526141.USD","BK4585","XBI","BK4581","BK4139","LABU","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635531970","title":"Mink Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635531970","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635531970?lang=en_us&edition=fundamental","pubTime":"2026-05-16 05:47","pubTimestamp":1778881642,"startTime":"0","endTime":"0","summary":"Mink Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryMink Therapeutics Inc INKT.OQ reported a quarterly adjusted loss of 57 cents per share for the quarter ended Marc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nL8N41S28F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635894940","title":"MiNK Therapeutics Q1 EPS $(0.57) Beats $(0.78) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2635894940","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635894940?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:36","pubTimestamp":1778845012,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.78) by 26.92 percent. This is a 18.57 percent increase over losses of $(0.70) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52592441/mink-therapeutics-q1-eps-0-57-beats-0-78-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089955","title":"MiNK Therapeutics Q1 FY26 net loss narrows to $2.74 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089955","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089955?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:31","pubTimestamp":1778844688,"startTime":"0","endTime":"0","summary":"Mink Therapeutics posted a first-quarter net loss of USD 2.74 million, narrowing from USD 2.77 million a year earlier, while loss per share improved to USD 0.57 from USD 0.70.Cash and cash equivalents fell to USD 9.53 million at March 31, 2026 from USD 13.36 million at end-2025, while cash used in operations rose to USD 1.73 million from USD 1.34 million a year earlier.During the quarter, it repaid about USD 5.2 million tied to the Agenus convertible note and raised about USD 3 million via its at-the-market sales agreement.MiNK initiated a randomized Phase 2 trial of agenT-797 in severe acute lung injury and critical illness, with preliminary data expected in the second half of 2026.CEO Jennifer Buell said the off-the-shelf iNKT therapy is designed for use without lymphodepletion or HLA matching in settings where speed and tolerability matter, including severe acute lung injury and critical illness.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nNDL1fLrLj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","AGEN","LU2095319765.USD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BN0W2V16.EUR","SG9999014021.USD","LU2210150020.SGD","BK4112","LU0314104364.USD","BK4588","INKT","SG9999014039.USD","SG9999014013.SGD","BK4139","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","NDAQ","IE00BKPKM429.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635008998","title":"BRIEF-MiNK Therapeutics Q1 EPS USD -0.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2635008998","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635008998?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844647,"startTime":"0","endTime":"0","summary":"BRIEF-MiNK Therapeutics Q1 EPS USD -0.57\n\n\nMay 15 (Reuters) - MiNK Therapeutics Q1 net income USD -2.7 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLXA44347:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635008962","title":"Mink Therapeutics Q1 EPS USD -0.57","url":"https://stock-news.laohu8.com/highlight/detail?id=2635008962","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635008962?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844604,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260515:nPLXA44347:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635899440","title":"Press Release: MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation","url":"https://stock-news.laohu8.com/highlight/detail?id=2635899440","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635899440?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"-- Randomized Phase 2 trial initiated for agenT-797 in severe acute lung. injury and respiratory distress, with preliminary data expected in the. -- AACR and ASGCT presentations showcase durable survival and. context-dependent iNKT activity in cancer and inflammatory lung disease. -- Non-dilutive collaborations expand MiNK's platform and potentiate. meaningful commercial revenue potential, while preserving focus on lead. Dr. Buell continued, \"What continues to distinguish agenT-797 is both its biology and its practicality. As an off-the-shelf iNKT cell therapy administered without lymphodepletion or HLA matching, agenT-797 is designed for settings where immune dysfunction drives poor outcomes and where speed, tolerability and deployability matter. We believe this is particularly relevant in severe acute lung injury and critical illness, where patients often face a cascade of respiratory failure, secondary infection and organ dysfunction with limited therapeutic options.\". MiNK initiate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRX","ATS","BK4161","BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.minktherapeutics.com;investor.minktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.0447},{"period":"1month","weight":0.1132},{"period":"3month","weight":0.1858},{"period":"6month","weight":-0.0185},{"period":"1year","weight":0.6086},{"period":"ytd","weight":0.0933}],"compareEarnings":[{"period":"1week","weight":-0.0382},{"period":"1month","weight":-0.0188},{"period":"3month","weight":0.0891},{"period":"6month","weight":0.0641},{"period":"1year","weight":0.2029},{"period":"ytd","weight":0.0638}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.041395},{"month":2,"riseRate":0.2,"avgChangeRate":-0.047548},{"month":3,"riseRate":0,"avgChangeRate":-0.079206},{"month":4,"riseRate":0.4,"avgChangeRate":0.010238},{"month":5,"riseRate":0,"avgChangeRate":-0.080325},{"month":6,"riseRate":0.4,"avgChangeRate":0.026293},{"month":7,"riseRate":0.25,"avgChangeRate":0.215487},{"month":8,"riseRate":0.25,"avgChangeRate":0.146012},{"month":9,"riseRate":0,"avgChangeRate":-0.132506},{"month":10,"riseRate":0.5,"avgChangeRate":-0.021174},{"month":11,"riseRate":0.6,"avgChangeRate":-0.066406},{"month":12,"riseRate":0.4,"avgChangeRate":-0.119867}],"exchange":"NASDAQ","name":"MiNK Therapeutics, Inc.","nameEN":"MiNK Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MiNK Therapeutics, Inc.,INKT,MiNK Therapeutics, Inc.股票,MiNK Therapeutics, Inc.股票老虎,MiNK Therapeutics, Inc.股票老虎国际,MiNK Therapeutics, Inc.行情,MiNK Therapeutics, Inc.股票行情,MiNK Therapeutics, Inc.股价,MiNK Therapeutics, Inc.股市,MiNK Therapeutics, Inc.股票价格,MiNK Therapeutics, Inc.股票交易,MiNK Therapeutics, Inc.股票购买,MiNK Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}